94 related articles for article (PubMed ID: 15217149)
21. Commentary: Novel therapies for cancer: why dirty might be better.
Fojo T
Oncologist; 2008 Mar; 13(3):277-83. PubMed ID: 18378537
[No Abstract] [Full Text] [Related]
22. Evaluation of c-kit (CD 117) expression as a prognostic factor in testicular germ cell tumors: an Izmir Oncology Group (IZOG) study.
Salman T; Yildiz E; Yildiz I; Yavuzer D; Unlu M; Varol U; Akyol M; Yildiz Y; Bayoglu V; Kucukzeybek Y; Alacacioglu A
J BUON; 2015; 20(4):1054-60. PubMed ID: 26416056
[TBL] [Abstract][Full Text] [Related]
23. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.
Lee JK; Hahn S; Kim DW; Suh KJ; Keam B; Kim TM; Lee SH; Heo DS
JAMA; 2014 Apr; 311(14):1430-7. PubMed ID: 24715074
[TBL] [Abstract][Full Text] [Related]
24. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R
Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062
[TBL] [Abstract][Full Text] [Related]
25. Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development.
Costa R; Shah AN; Santa-Maria CA; Cruz MR; Mahalingam D; Carneiro BA; Chae YK; Cristofanilli M; Gradishar WJ; Giles FJ
Cancer Treat Rev; 2017 Feb; 53():111-119. PubMed ID: 28104566
[TBL] [Abstract][Full Text] [Related]
26. Targeting Epidermal Growth Factor Receptor-Related Signaling Pathways in Pancreatic Cancer.
Philip PA; Lutz MP
Pancreas; 2015 Oct; 44(7):1046-52. PubMed ID: 26355547
[TBL] [Abstract][Full Text] [Related]
27. Systemic cancer therapy: evolution over the last 60 years.
Dy GK; Adjei AA
Cancer; 2008 Oct; 113(7 Suppl):1857-87. PubMed ID: 18798529
[TBL] [Abstract][Full Text] [Related]
28. [Rescue chemotherapy in testicular germ cell tumors].
Salazar Soler R; Maroto Rey P; Solà Rocabert C; López López JJ
Arch Esp Urol; 2000; 53(6):554-64. PubMed ID: 11002524
[TBL] [Abstract][Full Text] [Related]
29. Targeting c-Kit mutations: basic science to novel therapies.
Sattler M; Salgia R
Leuk Res; 2004 May; 28 Suppl 1():S11-20. PubMed ID: 15036937
[TBL] [Abstract][Full Text] [Related]
30. Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies.
Lim SM; Syn NL; Cho BC; Soo RA
Cancer Treat Rev; 2018 Apr; 65():1-10. PubMed ID: 29477930
[TBL] [Abstract][Full Text] [Related]
31. An in vivo model for receptor tyrosine kinase autocrine/paracrine activation: auto-stimulated KIT receptor acts as a tumor promoting factor in papillomavirus-induced tumorigenesis.
Kondoh G; Hayasaka N; Li Q; Nishimune Y; Hakura A
Oncogene; 1995 Jan; 10(2):341-7. PubMed ID: 7530826
[TBL] [Abstract][Full Text] [Related]
32. Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists.
Silvestri GA; Rivera MP
Chest; 2005 Dec; 128(6):3975-84. PubMed ID: 16354869
[TBL] [Abstract][Full Text] [Related]
33. High-dose chemotherapy in poor-risk germ-cell tumors.
Srinivas S
Oncology (Williston Park); 2000 Oct; 14(10):1419-23; discussion 1427-30, 1433-4. PubMed ID: 11098508
[TBL] [Abstract][Full Text] [Related]
34. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
Zhang K; Yuan Q
J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical profiling of receptor tyrosine kinases, MED12, and TGF-βRII of surgically resected small cell lung cancer, and the potential of c-kit as a prognostic marker.
Yokouchi H; Nishihara H; Harada T; Ishida T; Yamazaki S; Kikuchi H; Oizumi S; Uramoto H; Tanaka F; Harada M; Akie K; Sugaya F; Fujita Y; Takamura K; Kojima T; Higuchi M; Honjo O; Minami Y; Watanabe N; Goto A; Suzuki H; Dosaka-Akita H; Isobe H; Nishimura M; Munakata M
Oncotarget; 2017 Jun; 8(24):39711-39726. PubMed ID: 28055980
[TBL] [Abstract][Full Text] [Related]
36. Potential for molecularly targeted therapy against epidermal growth factor receptor ligands.
Miyamoto S; Fukami T; Yagi H; Kuroki M; Yotsumoto F
Anticancer Res; 2009 Mar; 29(3):823-30. PubMed ID: 19414315
[TBL] [Abstract][Full Text] [Related]
37. Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues.
Ulbright TM
Mod Pathol; 2005 Feb; 18 Suppl 2():S61-79. PubMed ID: 15761467
[TBL] [Abstract][Full Text] [Related]
38. [New molecules for therapeutic targets in cancer].
L'Allemain G; Bénard J
Bull Cancer; 2001 Dec; 88(12):1240-5. PubMed ID: 11792617
[No Abstract] [Full Text] [Related]
39. Testicular cancer: an oncological success story.
Einhorn EH
Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2630-2. PubMed ID: 10068265
[TBL] [Abstract][Full Text] [Related]
40. Biology of germ cell tumors.
Ma YT; Cullen MH; Hussain SA
Hematol Oncol Clin North Am; 2011 Jun; 25(3):457-71, vii. PubMed ID: 21570602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
